Systemic approaches in biliary tract cancers: a review in the era of multidirectional precision medicine
Authors:
- 24 November 2024
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 25 (18) , 2385-2397
Abstract
IntroductionDespite a rising incidence, biliary tract cancers (BTCs) are still considered a rare tumor entity. The disease's subtle clinical presentation and lack of effective early detection strategies often lead to a diagnosis at an advanced or unresectable stage, where curative options are limited.Areas coveredThis review provides an overview of current systemic therapies and emerging novel approaches for BTC. For decades, the combination of gemcitabine with cisplatin (GemCis) has been the standard of care for palliative treatment. However, since 2020, the diagnostic and therapeutic landscape for BTC has evolved considerably, not only in the first-line setting but also beyond, driven by the development of clinical trials exploring immunotherapy and molecularly targeted agents. Due to the high frequency of targetable genetic alterations in BTC patients, there is a growing emphasis on obtaining tissue or liquid biopsy samples to identify markers like microsatellite instability and other actionable oncogenic driver genes.Expert opinionEarly initiation of systemic therapies in combination with multimodal approaches is essential for maximizing survival outcomes in patients with BTC.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft
This publication has 131 references indexed in Scilit:
- Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world studyCancer Immunology, Immunotherapy, 2023
- Randomized phase III study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401‐ MITSUBA)Journal of Hepato-Biliary-Pancreatic Sciences, 2022
- The immunogenomic landscape of resected intrahepatic cholangiocarcinomaHepatology, 2021
- Postoperative adjuvant chemotherapy for resectable cholangiocarcinomaCochrane Database of Systematic Reviews, 2021
- Very Early Recurrence After Liver Resection for Intrahepatic CholangiocarcinomaJAMA Surgery, 2020
- Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studiesInternational Journal of Cancer, 2020
- Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract CancersJAMA Oncology, 2019
- Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancerBritish Journal of Surgery, 2018
- Biliary cancer: Utility of next‐generation sequencing for clinical managementCancer, 2016
- Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary AdenocarcinomaJAMA, 2012